CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy

详细信息    查看全文

• 作者：Begoñ ; a Vieites ; Marí ; a Á ; Ló ; pez-Garcí ; a ; Carolina Castilla ; Marí ; a J Herná ; ndez ; Michele Biscuola ; Lina Alfaro ; Marí ; a R Atienza ; Marí ; a Á ; Castilla and José ; Palacios
• 刊名：Histopathology
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：69
• 期：2
• 页码：239-249
• 全文大小：609K
• ISSN：1365-2559

文摘

Neoadjuvant therapy is used in many patients with breast cancer before surgery, with the aim of reducing the tumour size, allowing conservative resections. Sentinel node biopsy is a conservative procedure for handling the axilla in breast cancer; however, the use of this technique after neoadjuvant treatment is under discussion. For sentinel node assay, methods based on the detection of cytokeratin 19 (CK19) mRNA, such as one-step nucleic acid amplification (OSNA), are available. However, if systemic therapy could alter protein expression, then CK19 would not be a good target for analysing these nodes. The aim of this study was to evaluate the immunohistochemical expression of CK19 within different cancer types, and to compare its expression in breast tumours and axillary nodes before and after treatment.